Indigenous Kovacin Waiting for Approval: India Biotech Vaccine is recognized in 14 countries, yet why is it not trusted by the WHO?

News Desk, Amar Ujala, New Delhi

Published by: Pranjul Srivastava
Updated to Wednesday, 27 October 2021 12:38 PM IST

Summary

The World Health Organization will hold its next meeting on November 3 to add Kovoxin to its list of emergency uses. The WHO Technical Committee sought further clarification from the company.

Listen to the news

The World Health Organization has so far added the Kovid-19 vaccine of Pfizer, AstraZeneca, Johnson & Johnson, Modernna and Sinoform to the list of emergency uses against corona, but the Kovacin made in India is still awaiting WHO approval. At a WHO meeting on Tuesday, Bharat Biotech, the maker of Kovacin, expressed hope that the global organization would add Kovid-19 vaccines to its emergency list against Corona, but that did not happen.

The World Health Organization still doubts the validity and effectiveness of Covoxin. This is the reason why the technical committee of the World Health Organization has sought further clarification from Bharat Biotech Company of Hyderabad regarding Kovoxin. However, the World Health Organization has also said- ‘We hope that India will provide all the explanations regarding biotech Kovoxin by the end of this week. Therefore, the next meeting for Covoxin approval is now scheduled for November 3.

Why the WHO does not trust Kovoxin
The World Health Organization has clarified its position on Kovoxin. Last week, the WHO tweeted about covaccine, which requires a comprehensive evaluation of whether the vaccine is safe against corona. We cannot exceed safety standards to allow emergency use. The WHO says vaccines are safe and effective and require comprehensive evaluation.

Who said that –

Bharat Biotech applied on April 19

Bharat Biotech on April 19 applied for the inclusion of Kovoxin in the Emergency Consumer List. The company also submitted a variety of data to the WHO’s technical committee. However, the World Health Organization has now sought clarification on Covoxin’s ultimate benefit-risk assessment.

77.8 percent is effective
Kovoksin, India’s first domestic Kovid-19 vaccine, is 77.8 percent effective. These figures were submitted after the third phase trials conducted by the company. Bharat Biotech told the WHO that Covoxin has been approved in 14 countries and 70 million doses have been exported.

Expansion

The World Health Organization has so far added the Kovid-19 vaccine of Pfizer, AstraZeneca, Johnson & Johnson, Modernna and Synoform to the list of emergency uses against corona, but the Kovacin made in India is still awaiting WHO approval. At a WHO meeting on Tuesday, Bharat Biotech, the maker of Kovacin, expressed hope that the global organization would add Kovid-19 vaccines to its emergency list against Corona, but that did not happen.

The World Health Organization still doubts the validity and effectiveness of Covoxin. This is the reason why the technical committee of the World Health Organization has sought further clarification from Bharat Biotech Company of Hyderabad regarding Kovoxin. However, the World Health Organization has also said- ‘We hope that India will provide all the explanations regarding biotech Kovoxin by the end of this week. Therefore, the next meeting for Covoxin approval is now scheduled for November 3.

Why the WHO does not trust Kovoxin

The World Health Organization has clarified its position on Kovoxin. Last week, the WHO tweeted about covaccine, which requires a comprehensive evaluation of whether the vaccine is safe against corona. We cannot exceed safety standards to allow emergency use. The WHO says vaccines are safe and effective and require comprehensive evaluation.

Who said that –

‘In order for a vaccine to be included in the Emergency Use List, the manufacturer must provide the necessary and sufficient data over a period of time. The time frame will depend on whether the company can provide adequate data on vaccine quality, safety, efficacy, and evaluation of vaccine use in developing and underdeveloped countries.


Bharat Biotech applied on April 19

Bharat Biotech applied on April 19 to add Kovoxin to its list of emergency uses. The company also submitted a variety of data to the WHO’s technical committee. However, the World Health Organization has now sought clarification on Covoxin’s ultimate benefit-risk assessment.

77.8 percent is effective

Kovoksin, India’s first domestic Kovid-19 vaccine, is 77.8 percent effective. These figures were submitted after the third phase trials conducted by the company. Bharat Biotech told the WHO that Covoxin has been approved in 14 countries and 70 million doses have been exported.

.



Source link

Leave a Comment